The Pulse
Novo’s Q1 lands: Wegovy pill clocks $353M in its first three months
On May 6, Novo Nordisk reported Q1 2026 results. The Wegovy pill, launched January 5, did roughly $353M in its first three months and is now reaching over 1 million patients. Wegovy holds 65% of new GLP-1 prescriptions in the U.S.
Novo raised full-year guidance and described the oral launch as the strongest GLP-1 ramp on record.
This is the moment “wait and see” stops being a safe stance for retention teams. The oral cohort is no longer hypothetical. The flows weren’t built for it.
Hims & Hers Q1 print confirms the compounding squeeze on retention economics
Hims & Hers reported Q1 2026 this week. In the run-up, Wall Street had cut EPS estimates roughly 78% over the prior 90 days. Revenue still growing modestly. Earnings compressing hard.
The pressure points cited: FDA compounding crackdown, end of the semaglutide shortage period, and the post-Novo product mix shift.
Even if you’re not public, the print is the cleanest view of what telehealth retention economics look like under tighter compounding rules and a compressed price floor. Pull the transcript. Listen to the call, not just the headline.
Q1 2026 digital health funding hits $4B with 12 mega-rounds taking 59% of capital
Q1 2026 closed at $4B (Rock Health) to $7.4B (HitConsultant): the strongest first quarter since the pandemic peak. Average deal size hit $36.7M, the highest single-quarter mark since Q4 2021.
Twelve mega-rounds at $100M+ captured 59% of total capital. M&A jumped 47%. Sword bought Kaia for $285M. Spring bought Alma. Wisp bought TBD. Hims acquired Eucalyptus to go international.
If your exit window is the next 18 to 24 months, the line item that moves your multiple isn't topline. It's post-month-3 retention curves and expansion revenue per patient.
The Deep Dive
Oral GLP-1 is on a short timeline. Most brands won't see it in their funnel today, but the architecture you build before access opens decides who ships in days versus quarters.
The Wegovy pill is in over 1 million patients four months into launch, mostly through Novo's launch partners (Hims, Ro, major retail). Lilly's Foundayo was approved April 1 and is rolling out broader through retail and telehealth.
If you're not a launch partner and you're not offering compounded oral, your current GLP-1 funnel is close to 100% injection. The dual-format problem is forward-looking, not an operational fire today.
That's the trap. The architecture takes weeks to build. The patient cohort arrives faster than that.
When the mix lands, the destination is roughly 50/30/20: half of new patients prefer oral, 30% prefer injection, 20% are indifferent and follow the provider's recommendation. Same molecule, different commitment ritual, different side-effect curve, different cancellation reasons. A single shared sequence loses the oral cohort in week one.
The four splits below are the architecture. Build them now while your base is still mostly injection. The day access lands, you flip the flag and ship.
Same logic applies in hormone therapy, hair loss, peptides, and so on. Anywhere you offer more than one delivery format (injection vs cream, oral vs topical, injection vs sublingual), the lifecycle has to recognize it.
1. Onboarding has to split at week 1.
The injection patient needs syringe education, injection-site rotation, and a weekly self-administration ritual reinforced.
The pill patient needs a fasting protocol (oral semaglutide is taken on an empty stomach, water only, before food), a daily reminder system, and a different week-1 expectation set.
Week 1 emails for both should reach the same emotional place: you started, you're doing it right, here's what's coming. The operational content is completely different.
2. Side-effect content peaks at different points.
Injectable GLP-1 patients hit nausea and GI peak around days 7 to 14, after the first few doses build up. Pill patients report more GI discomfort in the first 7 days.
If your day 3-14 side-effect content was tuned for the injection curve, oral patients are getting "this should pass soon" messaging while they're still mid-week-one nausea. They drop off before the medication starts working.
The fix is a parallel side-effect track keyed to format, not to days-since-signup.
3. Adherence is a different problem entirely.
The injection has built-in retention. Patients tie the dose to a day of the week. Sunday morning. Tuesday night. The act itself is a commitment ritual.
The pill blends in. A daily pill on the kitchen counter looks like a multivitamin. Patients forget. Adherence reminders that injection patients don't need become non-negotiable for oral patients.
A daily SMS or push notification cadence in the first 30 days does more work for the pill cohort than a weekly recap email ever did for the injection cohort.
4. Cancellation reasons split too.
Injection patients cancel for "I don't want to inject anymore" or "the weekly reminder is stressful."
Pill patients cancel for "I keep forgetting" or "it's not as effective as I expected." The efficacy gap between oral and injectable semaglutide is real, and the patient sees it.
Reason-specific cancellation flows that group these two cohorts together miss both. Each format needs its own save offer and its own re-engagement angle.
Takeaway: Add a treatment-format flag to your CRM this month, even if every patient is currently tagged with one format today. Then audit every existing flow for whether it assumes a single format. The brands that win the oral expansion are not the ones with the most molecules. They're the ones whose flag, flows, and content variants were built before access landed. Same exercise, same payoff, in any category with multiple delivery formats.
Quick Takes
The pill blends in. The flow has to fight that.
A weekly injection is a built-in retention mechanism. A daily pill is not.
For the oral cohort, your first 30 days needs to do the work the injection ritual did automatically. SMS reminders, habit-anchoring (next to coffee, before brushing teeth), a check-in at day 14 that explicitly normalizes “did you forget a dose? here’s how to get back on track.”
If your pill patients are churning faster than your injection patients in month 2, this is why.
Read the Hims call for what private telehealth looks like now.
Hims just reported Q1. Whatever the headline EPS, listen to what they said about lifecycle revenue per patient and the post-Novo product mix.
That’s the most honest view of what telehealth retention economics look like under the new rules. Compounding tighter. Branded prices easing. Attribution windows shrinking. And a public scoreboard.
If you’re a private comp, the call is the cheapest market research you’ll get all year.
One Thing to Try
Add a treatment_format property to your CRM this week. Values: oral, injection, unknown. Backfill from fulfillment data, even if every patient ends up tagged injection today.
Take the biggest sequence you have, the post-purchase or first-30-days flow that touches the most patients. Duplicate it. Rename one copy "format: oral" and one "format: injection."
Change exactly one thing in each: the day 7 side-effect content. Pill variant addresses week 1 GI discomfort. Injection variant addresses days 7-14 nausea peak. Wire the routing on the new property.
If you already have both cohorts, watch unsubscribe and day-30 retention by format. You'll know within 30 days whether format-specific content is moving the needle.
If you're still 100% injection, the validation is structural. Run a test patient through each branch. Confirm the routing fires, merge tags resolve, unsubscribe behavior is correct. The day access opens, you're shipping correct content from day one instead of building the parallel track under deadline.
If retention is your biggest revenue leak, that’s what we fix. growthtrigger.xyz
Reply to this with your biggest retention challenge. I read and respond to every single one.